Risk of Dental Discoloration and Enamel Dysplasia in Children Exposed to Tetracycline and Its Derivatives
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To examine the risk of dental abnormalities after exposure to tetracycline and its derivatives (TCs) in Korean children. Materials and Methods: Children aged 0–17 years with a claim for prescriptions of TCs between 2002 and 2015 were identified from the Sample Research Database 2.0 of the National Health Insurance Service. Children not exposed to TCs were selected as the control group by matching sex and age (1:4). Cumulative incidence rate and relative risk of dental abnormalities after TCs exposure were investigated. Results: The 10-year cumulative incidence rate in the 0–12 years group was 3.1% [95% confidence interval (CI), 2.3–3.9]. The 10year cumulative incidence rates were 7.0%, 1.9%, and 1.6% in the 0–7, 8–12, and 13–17 years age groups (95% CI: 4.7–9.3, 1.2–2.6, and 1.3–1.9, respectively). There was no significant difference in the risk of dental abnormalities according to TC exposure among the age groups of 0–7 years [adjusted hazard ratio (aHR)=1.0], 8–12 years (aHR=1.1), and 13–17 years (aHR=1.2). Conclusion: Short-term exposure to TCs does not appear to increase the risk of dental abnormalities in children aged 0–7 and 0–12 years. Restrictions on the use of TCs in children aged 8–12 years, in some countries, may warrant consideration.
Abstract
Purpose: To examine the risk of dental abnormalities after exposure to tetracycline and its derivatives (TCs) in Korean children. Materials and Methods: Children aged 0–17 years with a claim for prescriptions of TCs between 2002 and 2015 were identified from the Sample Research Database 2.0 of the National Health Insurance Service. Children not exposed to TCs were selected as the control group by matching sex and age (1:4). Cumulative incidence rate and relative risk of dental abnormalities after TCs exposure were investigated. Results: The 10-year cumulative incidence rate in the 0–12 years group was 3.1% [95% confidence interval (CI), 2.3–3.9]. The 10year cumulative incidence rates were 7.0%, 1.9%, and 1.6% in the 0–7, 8–12, and 13–17 years age groups (95% CI: 4.7–9.3, 1.2–2.6, and 1.3–1.9, respectively). There was no significant difference in the risk of dental abnormalities according to TC exposure among the age groups of 0–7 years [adjusted hazard ratio (aHR)=1.0], 8–12 years (aHR=1.1), and 13–17 years (aHR=1.2). Conclusion: Short-term exposure to TCs does not appear to increase the risk of dental abnormalities in children aged 0–7 and 0–12 years. Restrictions on the use of TCs in children aged 8–12 years, in some countries, may warrant consideration.
참고문헌 (24)
- Nelson ML, "The history of the tetracyclines", Ann N Y Acad Sci, 1241, pp.17~32 (2011)
- Cross R, "Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?", Expert Opin Drug Saf, 15, pp.367~382 (2016)
- Shwachman H, "The tetracyclines : applied pharmacology", Pediatr Clin North Am, 3, pp.295~303 (1956)
- Grossman ER, "Tetracyclines and permanent teeth : the relation between dose and tooth color", Pediatrics, 47, pp.567~570 (1971)
- Forti G, "Doxycycline and the teeth", Lancet, 1, pp.782~ (1969)
- Wormser GP, "How safe is doxycycline for young children or for pregnant or breastfeeding women?", Diagn Microbiol Infect Dis, 93, pp.238~242 (2019)
- Ahn JG, "Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children : a systematic review and meta-analysis", BMC Infect Dis, 21, pp.1003~ (2021)
- Meyer Sauteur PM, "Infection with and carriage of Mycoplasma pneumoniae in children", Front Microbiol, 7, pp.329~ (2016)
- Chen YC, "Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia", Emerg Infect Dis, 26, pp.1382~1391 (2020)
- Kawai Y, "Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients", Antimicrob Agents Chemother, 57, pp.4046~4049 (2013)
- 이은, "Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children", Clinical and Experimental Pediatrics, 60(5), pp.151~157 (2017), 대한소아청소년과학회
- Volovitz B, "Absence of tooth staining with doxycycline treatment in young children", Clin Pediatr(Phila), 46, pp.121~126 (2007)
- Todd SR, "No visible dental staining in children treated with doxycycline for suspected Rocky mountain spotted fever", J Pediatr, 166, pp.1246~1251 (2015)
- Zhu Z, "Tigecycline-induced tooth discoloration in children younger than eight years", Antimicrob Agents Chemother, 65, pp.e0085421~ (2021)
- Conchie JM, "The incidence of staining of permanent teeth by the tetracyclines", Can Med Assoc J, 103, pp.351~356 (1970)
- Pöyhönen H, "Dental staining after doxycycline use in children", J Antimicrob Chemother, 72, pp.2887~2890 (2017)
- Wallman IS, "Teeth pigmented by tetracycline", Lancet, 1, pp.827~829 (1962)
- Boast A, "QUESTION 1 : teething issues : can doxycycline be safely used in young children?", Arch Dis Child, 101, pp.772~774 (2016)
- Moffitt JM, "Prediction of tetracycline-induced tooth discoloration", J Am Dent Assoc, 88, pp.547~552 (1974)
- Guggenheimer J, "Tetracyclines and the human dentition", Compend Contin Educ Dent(Lawrenceville), 5, pp.245~248 (1984)
- Schach von Wittenau M, "Some pharmacokinetic aspects of doxycycline metabolism in man", Chemotherapia(Basel), (13), pp.41-50~41 (1968)[DOI]
- McIntosh HA, "Tetracycline-induced tooth changes, part 4. Discoloration and hypoplasia induced by tetracycline analogues", Med J Aust, 1, pp.114~119 (1970)
- Red book: 2018-2021 report of the committee on infectious diseases, "Committee on Infectious Diseases", American Academy of Pediatrics, 905~906 (2018)
- Gaillard T, "The end of a dogma : the safety of doxycycline use in young children for malaria treatment", Malar J, 16, pp.148~ (2017)